Serum progranulin level is a novel tool for monitoring disease activity of dermatomyositis with antimelanoma differentiation-associated protein 5 antibodies

Asami Fujii MD | Yuki H. Mizutani MD, PhD | Miho Kawamura MD | Kanako Matusyama MD, PhD | Yoko Mizutani MD, PhD | En Shu MD, PhD | Mariko Seishima MD, PhD

Department of Dermatology, Gifu University Graduate School of Medicine, Gifu, Japan

Correspondence
Mariko Seishima, MD, PhD, Department of Dermatology, Gifu University Graduate School of Medicine, 1-1 Yanaido, Gifu 501-1194, Japan.
Email: marikoseishima@yahoo.co.jp

Abstract
Objectives: Dermatomyositis (DM) is an autoimmune disease that presents with a wide variety of clinical manifestations. Patients with DM or clinically amyopathic dermatomyositis (CADM) with antimelanoma differentiation-associated protein 5 (anti-MDA5) antibodies are frequently associated with interstitial pneumonia, especially rapidly progressive interstitial lung disease. Progranulin (PGRN) is an autocrine growth factor involved in inflammation. Elevated serum PGRN levels have been reported in the patients with systemic lupus erythematosus and rheumatoid arthritis. However, they have not been precisely studied in DM/CADM. We assessed PGRN levels as a potential biomarker for DM/CADM with anti-MDA5 antibodies.

Methods: Twenty-four DM/CADM patients with anti-MDA5 antibodies, 12 patients without anti-MDA5 antibodies, and eight healthy volunteers were enrolled. We measured serum PGRN levels and compared them between the anti-MDA5 antibody-positive and antibody-negative groups. They were also measured before and after the start of treatment in anti-MDA5 antibody-positive patients. We examined the correlations between serum PGRN levels and laboratory data such as serum KL-6 and ferritin levels.

Results: Patients with DM/CADM, especially those with anti-MDA5 antibodies, had significantly higher serum PGRN levels than healthy individuals. They decreased after the start of treatment. Serum PGRN levels were positively correlated with serum KL-6 and ferritin levels, and anti-MDA5 antibody titers.

Conclusions: This is the first study to show that PGRN levels were significantly elevated in the sera of DM/CADM patients, particularly in those with anti-MDA5 antibodies. PGRN may be a useful biomarker of disease activity. However, further studies are required to reveal the mechanisms of PGRN in DM/CADM more precisely.

Keywords
anti-MDA5 antibodies, collagen diseases, dermatomyositis, interstitial lung disease, progranulin
INTRODUCTION

Dermatomyositis (DM) is a systemic autoimmune and inflammatory disease that involves not only the muscle and skin, but also several other organs, such as the lungs and joints. Clinically amyopathic DM (CADM) is a distinct subtype of DM that causes the same cutaneous symptoms as classic DM, but with little or no evidence of muscular manifestations. Disease-specific autoantibodies, known as myositis-specific autoantibodies, are strongly associated with distinct clinical phenotypes and are used to classify patients into groups with more homogenous clinical features. These include antibodies against melanoma differentiation-associated protein 5 (MDA5; anti-CADM 140 antibody), aminoacyl-tRNA synthetases, Mi-2 protein, transcriptional intermediary factor-1 (TIF1; anti-155/140 antibody), and NXP-2.

Patients with MDA5 antibodies have a high rate of concomitant interstitial lung disease (ILD), especially at risk for rapidly progressive interstitial lung disease (RP-ILD), and usually do not show muscular symptoms. In DM or CADM (DM/CADM) with anti-MDA5 antibodies, three different phenotypes have recently been reported: RP-ILD group with a very high mortality rate, pure dermatomyositis (DM) (CADM) is a distinct subtype of DM that causes the same cutaneous symptoms as classic DM, but with little or no evidence of muscular manifestations. Disease-specific autoantibodies, known as myositis-specific autoantibodies, are strongly associated with distinct clinical phenotypes and are used to classify patients into groups with more homogenous clinical features. These include antibodies against melanoma differentiation-associated protein 5 (MDA5; anti-CADM 140 antibody), aminoacyl-tRNA synthetases, Mi-2 protein, transcriptional intermediary factor-1 (TIF1; anti-155/140 antibody), and NXP-2.

Patients with MDA5 antibodies have a high rate of concomitant interstitial lung disease (ILD), especially at risk for rapidly progressive interstitial lung disease (RP-ILD), and usually do not show muscular symptoms. In DM or CADM (DM/CADM) with anti-MDA5 antibodies, three different phenotypes have recently been reported: RP-ILD group with a very high mortality rate, pure dermatomyositis (DM) (CADM) is a distinct subtype of DM that causes the same cutaneous symptoms as classic DM, but with little or no evidence of muscular manifestations. Disease-specific autoantibodies, known as myositis-specific autoantibodies, are strongly associated with distinct clinical phenotypes and are used to classify patients into groups with more homogenous clinical features. These include antibodies against melanoma differentiation-associated protein 5 (MDA5; anti-CADM 140 antibody), aminoacyl-tRNA synthetases, Mi-2 protein, transcriptional intermediary factor-1 (TIF1; anti-155/140 antibody), and NXP-2.

Clinical characteristics, treatments, and clinical courses

We compared the skin lesions (Gottron's papules/sign, heliotrope rash, mechanics' hands, palmar papules/erythema, ulcer, calcinosis, periungual hemorrhage, and Raynaud's phenomenon; Figure 1) and general symptoms (fever, muscular symptoms, ILD, and arthropathy) between the anti-MDA5 antibody-positive and antibody-negative groups and followed at least 6 months after the start of treatment. Treatment outcomes and death rates within 6 months were compared.

Laboratory data

We measured the levels of KL-6, C-reactive protein (CRP), erythrocyte sedimentation rate at 1 h (ESR), ferritin, and lactate dehydrogenase (LD) before and after the start of treatment, at approximately 1-month interval.

Measurement of serum levels of PGRN

Serum PGRN concentrations were measured by enzyme-linked immunosorbent assay (ELISA; CircuLex Human Progranulin ELISA Kit, MBL) in duplicate according to the manufacturer's instructions and assessed using a spectrophotometer (Epoch, BioTek Instruments). The sera and ELISA Kits were stored at −80°C before use. The PGRN levels were measured before and after the start of the treatment at approximately 1-month interval.

Statistical analyses

Data analysis was performed using Excel Statistics, 2012 (Social Survey Information). Statistically significant differences between groups were calculated using the chi-square test for categorical variables and the Mann-Whitney U-test for nonparametric, continuous variables. Pearson's correlation was used to examine the correlation between two continuous variables, p < 0.05 was considered statistically significant.

RESULTS

Clinical findings and clinical course

Patients with anti-MDA5 antibodies had ILD more frequently, and fever and muscular symptoms less frequently. With regard to cutaneous manifestations, palmar papules/erythema (Figure 1) was...
observed more often, but heliotrope rash less in these patients. However, Gottron’s papules/sign, mechanics’ hands, ulcer, calcinosis, and periungual hemorrhage were not different between two groups (Figure 1 and Table 1).

Of the 24 patients with anti-MDA5 antibody-positive DM/CADM, there were four patients in the RP-ILD group, 15 of in the pure dermato-rheumatologic symptom group, and five in the severe skin vasculopathy group with myositis.15

Steroid pulse therapy was administered more often in patients with anti-MDA5 antibodies (Table 1). Of the 24 DM/CADM patients with anti-MDA5 antibodies, three died in the following 6 months. Four patients experienced recurrence with re-elevation of PGRN levels associated with increased antibody titers, while re-elevation of KL-6 and ferritin levels was seen, in three patients and in one patient, respectively.

3.2 | Serum PGRN levels in DM/CADM patients vs healthy volunteers

The mean serum PGRN level in DM/CADM patients before initiating treatment was 128 ± 77 ng/ml (range 27-430), which was significantly elevated compared to that in healthy volunteers, 49 ± 6 ng/ml (range: 39-56) (\(p < 0.001\)). The mean serum PGRN level in DM/CADM patients after the initiation of treatment was 75 ± 53 ng/ml (range: 25-262), which was also significantly higher than that in healthy adults (\(p < 0.001\)) (Figure 2).

3.3 | Serum PGRN levels in MDA5 antibody-positive vs MDA5 antibody-negative DM/CADM patients

Among the DM/CADM patients, serum PGRN levels were compared between anti-MDA5 antibody-positive and anti-MDA5 antibody-negative patients. Serum PGRN levels were significantly higher in the former group, both before and after the start of treatment (\(p < 0.01\)), and were also found to have reduced after the start of treatment in both patient groups (Figure 3).

3.4 | Clinical course and serum PRGN levels

Serum PGRN levels gradually decreased with treatment in eight DM/CADM patients with anti-MDA5 antibodies (Figure 4A), who were followed-up periodically for at least 6 months. The mean PGRN levels decreased after treatment initiation (Figure 4B).

3.5 | Correlation between laboratory data and serum PRGN levels

Serum PGRN levels were positively correlated with anti-MDA-5 antibody titers, and ferritin and KL-6 levels. However, CRP, ESR, and LD levels did not correlate with PGRN levels (Figure 5).
Progranulin is an extracellular glycoprotein containing seven and one-half repeats of cysteine-rich motifs. PGRN is synthesized by macrophages and is cleaved by extracellular proteases, such as proteinase 3 (PR3) and elastase, into granulin (GRN), which ranges in molecular weight from 6 to 25 kDa. Moreover, PGRN and/or GRN act as soluble cofactors for toll-like receptor 9 (TLR9) signaling and enhance it. Serum PGRN levels are significantly elevated in SLE patients in parallel with the disease activity. PGRN may play a role in the pathogenesis of SLE, partly by enhancing the TLR9 signaling and interleukin (IL)-6 production.

The accumulation of ferritin-producing macrophages has been shown in a CADM-related acute interstitial pneumonia autopsy case. Since macrophage activation is also considered to underlie the pathogenesis of DM/CADM, serum IL-6 and ferritin can be biomarkers of DM/CADM. However, elevated levels of these markers are not limited to myositis-specific antibodies (Figure 5).

Because PGRN is highly expressed in macrophages, elevation of serum PGRN levels in DM with acute IP also reflects macrophage activation as that of ferritin. PGRN is reported to be important in the initiation of inflammation by recruiting fibroblasts, macrophages, and neutrophils to the site of inflammation. PGRN is also converted to GRN by the elastase that is produced by leukocytes; however, recent mouse studies have shown that GRN possesses inflammatory functions. Thus, PGRN may be converted to GRN in the lungs and be associated with the early phase of pathogenesis of DM with acute ILD. However, it is difficult to investigate the function of GRN in human studies since the measurement of GRNs is not currently available. In our study, serum PGRN levels showed a significant positive correlation with serum anti-MDA5 antibody titers, and serum levels of ferritin and

| TABLE 1 Clinical findings and clinical course of DM/CADM with and without anti-MDA5 antibodies |
|-----------------------------------------------|-------------------------------------------------|---------------------|---------------------|---------------------|
| DM/CADM with anti-MDA5 antibody n = 24 (%)   | DM/CADM without anti-MDA5 antibody n = 12 (%)   | p value             |
| A) Background                                |                                                 |                     |
| Gender (females) 18 (75)                     | 6 (50)                                          | 0.134               |
| Age 51.8 ± 23.4                               | 54.6 ± 20.8                                     | 0.102               |
| B) General symptoms                          |                                                 |                     |
| Fever 4 (16.7)                               | 7 (58.3)                                        | <0.05*              |
| Muscular symptoms 2 (8.3)                    | 12 (100)                                        | <0.001***           |
| ILDb                                         | 6 (50)                                          | <0.01**             |
| Arthropathy 6 (25)                            | 5 (41.7)                                        | 0.306               |
| C) Cutaneous manifestations                  |                                                 |                     |
| Gottron's papules/sign 24 (100)               | 11 (91.7)                                       | 0.151               |
| Heliotrope rash 11 (45.8)                     | 11 (91.7)                                       | <0.05*              |
| Mechanics' hands 18 (75)                     | 6 (50)                                          | 0.134               |
| Palmar erythema/papule 16 (66.7)              | 2 (16.7)                                        | <0.01**             |
| Ulcer 4 (16.7)                               | 1 (8.3)                                         | 0.496               |
| Calcinosis 1 (4.2)                            | 2 (16.7)                                        | 0.201               |
| Periungual hemorrhage 10 (41.7)               | 4 (33.3)                                        | 0.629               |
| Raynaud's phenomenon 3 (12.5)                 | 1 (8.3)                                         | 0.708               |
| D) Treatment                                 |                                                 |                     |
| Systemic steroids 24 (100)                    | 10 (83.3)                                       | <0.05*              |
| Steroid pulse therapy 16 (66.7)               | 2 (16.7)                                        | <0.01**             |
| Immunosuppressants 20 (83.3)                  | 8 (66.7)                                        | 0.257               |
| IVCYc                                        | 4 (33.3)                                        | 0.629               |
| E) Clinical courses                          |                                                 |                     |
| Death within 6 months 3 (12.5)                | 2 (16.7)                                        | 0.733               |

aDermatomyositis or clinically amyopathic dermatomyositis.
bInterstitial lung disease.
cIntravenous cyclophosphamide.
*p < 0.05.
**p < 0.01.
***p < 0.001.

4 | DISCUSSION

Progranulin is an extracellular glycoprotein containing seven and one-half repeats of cysteine-rich motifs. PGRN is synthesized by macrophages and is cleaved by extracellular proteases, such as proteinase 3 (PR3) and elastase, into granulin (GRN), which ranges in molecular weight from 6 to 25 kDa. Moreover, PGRN and/or GRN act as soluble cofactors for toll-like receptor 9 (TLR9) signaling and enhance it. Serum PGRN levels are significantly elevated in SLE patients in parallel with the disease activity. PGRN may play a role in the pathogenesis of SLE, partly by enhancing the TLR9 signaling and interleukin (IL)-6 production.

The accumulation of ferritin-producing macrophages has been shown in a CADM-related acute interstitial pneumonia autopsy case. Since macrophage activation is also considered to underlie the pathogenesis of DM/CADM, serum IL-6 and ferritin can be biomarkers of DM/CADM. However, elevated levels of these markers are not limited to myositis-specific antibodies (Figure 5).

Because PGRN is highly expressed in macrophages, elevation of serum PGRN levels in DM with acute IP also reflects macrophage activation as that of ferritin. PGRN is reported to be important in the initiation of inflammation by recruiting fibroblasts, macrophages, and neutrophils to the site of inflammation. PGRN is also converted to GRN by the elastase that is produced by leukocytes and other cells; however, recent mouse studies have shown that GRN possesses inflammatory functions. Thus, PGRN may be converted to GRN in the lungs and be associated with the early phase of pathogenesis of DM with acute ILD. However, it is difficult to investigate the function of GRN in human studies since the measurement of GRNs is not currently available. In our study, serum PGRN levels showed a significant positive correlation with serum anti-MDA5 antibody titers, and serum levels of ferritin and
Recent studies have suggested serum ferritin level is a marker for severity of acute progressive ILD in DM and CADM patients. Serum ferritin levels in CADM patients with acute ILD are already elevated in the early stages of the disease, before the progression of ILD.

KL-6 reflects the regeneration and proliferation of pneumocytes after damage to the pulmonary tissue. Thus, PGRN could also be an acute marker for ILD like ferritin as well as a regeneration marker like KL-6.

Macrophage-derived PGRN is a key regulatory factor in inflammation and wound healing. Several reports in recent years have concluded that serum PGRN level is elevated in conditions such as breast cancer, rheumatoid arthritis, and systemic lupus erythematosus and that it may be a prognostic factor. Accordingly, PGRN is not a disease-specific marker, rather a probable marker of immune activation.

In the present study, patients with DM/CADM, especially those with anti-MDA5 antibody-positive, had significantly higher serum PGRN levels than healthy individuals. A significantly higher serum PGRN levels have been reported in DM/CADM patients complicated by acute/subacute ILD. Among the anti-MDA5 antibody-positive patients studied in this study, all except one had RP-ILD. In both DM/CADM patients with or without anti-MDA5 antibodies, serum PGRN levels decreased with the start of treatments. On recurrence, serum PGRN levels increased rapidly with an increase in antibody titers in all recurrent cases, and serum levels of ferritin and KL-6 did not in all of the cases.

To our knowledge, this is the first study to show that PGRN levels were significantly elevated in the sera of DM/CADM patients, particularly in those with MDA5 antibodies, and that its concentrations...
were positively correlated with the anti-MDA5 antibody titers, ferritin, and KL-6 levels. Nonetheless, we must acknowledge a limitation of this study. The sample size in this study was small, thus affecting the reliability of the results. Statistical tests usually require a larger sample size to justify that the effect did not occur by chance alone.

Our study showed that PGRN could be a useful biomarker for disease activity in DM patients with ILD. These findings will provide new insights into the pathogenesis and treatment of DM. Further studies are required to reveal the mechanisms of PGRN in human autoimmune diseases more precisely.

ACKNOWLEDGMENTS
The authors would like to thank Mrs Kayoko Tanaka, Mrs Naoko Abe, and Mrs Miho Mabuchi for assisting with data collection.

CONFLICT OF INTEREST
The authors declares no conflict of interest.

AUTHOR CONTRIBUTIONS
AF had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. YHM, MK, KM, YM, and ES contributed to the acquisition, analysis, and interpretation of the data. MS contributed to the drafting of the manuscript and supervision of the study. All authors read and approved the final manuscript.

DECLARATION SECTION
Approval of the research protocol: The protocol for this study was approved by the Ethical Committee of the Gifu University Graduate School of Medicine (approval ID: 2017-146).
Informed consent: Informed consent was obtained from all participants and healthy volunteers enrolled in this study.
Registry and the Registration No. of the study/trial: N/A.
Animal Studies: N/A.

REFERENCES
1. Callen JP. Dermatomyositis. Lancet. 2000;355:53–7.
2. Matsushita T, Mizumaki K, Kano M, Yagi N, Tennichi M, Takeuchi A, et al. Antimelanoma differentiation-associated protein 5 antibody level is a novel tool for monitoring disease activity in rapidly progressive interstitial lung disease with dermatomyositis. Br J Dermatol. 2017;176:395–402.
3. Sato S, Hirakata M, Kuwana M, Suwa A, Inada S, Mimori T, et al. Autoantibodies to a 140-kd polypeptide, CADM-140, in Japanese patients with clinically amyopathic dermatomyositis. Arthritis Rheum. 2005;52:1571–6.
4. Sato S, Hoshino K, Sato T, Fujita T, Kawakami Y, Fujita T, et al. RNA helicase encoded by melanoma differentiation-associated gene 5 is a major autoantigen in patients with clinically amyopathic dermatomyositis: Association with rapidly progressive interstitial lung disease. Arthritis Rheum. 2005;52:2193–200.
5. Nakashima R, Imura Y, Kobayashi S, Yuka N, Yoshifuji H, Nojima T, et al. The RIG-I-like receptor IFIH1/MDA5 is a dermatomyositis-specific autoantigen identified by the anti-CADM-140 antibody. Rheumatology. 2010;49:433–40.
6. Matsushita T, Hasegawa M, Fujimoto M, Hamaguchi Y, Komura K, Hirano T, et al. Clinical evaluation of anti-aminoacyl tRNA synthetase antibodies in Japanese patients with dermatomyositis. J Rheumatol. 2007;34:1012–8.
7. Hamaguchi Y, Fujimoto M, Matsushita T, Kaji K, Komura K, Hasegawa M, et al. Common and distinct clinical features in adult patients with anti-aminoacyl-tRNA synthetase antibodies: heterogeneity within the syndrome. PLoS One. 2013;8:e60442.
8. Komura K, Fujimoto M, Matsushita T, Kaji K, Kondo M, Hirano T, et al. Prevalence and clinical characteristics of anti-Mi-2 antibodies in Japanese patients with dermatomyositis. J Dermatol Sci. 2005;40:215–7.
9. Targoff IN, Mamyrova G, Trieu EP, Perurena O, Koneru B, O’Hanlon TP, et al. A novel autoantibody to a 155-kd protein is associated with dermatomyositis. Arthritis Rheum. 2006;54:3682–9.
10. Kaji K, Fujimoto M, Hasegawa M, Kondo M, Saito Y, Komura K, et al. Identification of a novel autoantibody reactive with 155 and 140 kDa nuclear proteins in patients with dermatomyositis: an association with malignancy. Rheumatology. 2007;46:25–8.

ORCID
Mariko Seishima https://orcid.org/0000-0003-0007-3632

FIGURE 5  Correlation between the serum progranulin levels and antimelanoma differentiation-associated protein 5 (anti-MDA5) antibody titers, KL-6, C-reactive protein (CRP), erythrocyte sedimentation rate at 1 h (ESR), ferritin, and lactate dehydrogenase (LD) levels
11. Ichimura Y, Matsushita T, Hamaguchi Y, Kaji K, Hasegawa M, Tanino Y, et al. Anti-NXP2 autoantibodies in adult patients with idiopathic inflammatory myopathies: possible association with malignancy. Ann Rheum Dis. 2012;71:710–3.

12. Hamaguchi Y, Kuwana M, Hoshino K, Hasegawa M, Kaji K, Matsushita T, et al. Clinical correlations with dermatomyositis-specific autoantibodies in adult Japanese patients with dermatomyositis: a multicenter cross-sectional study. Arch Dermatol. 2011;147:391–8.

13. Gono T, Kawaguchi Y, Satoh T, Kuwana M, Katsumata Y, Takagi K, et al. Clinical manifestation and prognostic factor in anti-melanoma differentiation-associated gene 5 antibody-associated interstitial lung disease as a complication of dermatomyositis. Rheumatology. 2010;49:1713–9.

14. Moghadam-Kia S, Oddis CV, Sato S, Kuwana M, Aggarwal R. Anti-melanoma differentiation-associated gene 5 antibody-observed acute interstitial lung disease is associated with rapidly progressive lung disease and poor survival in US patients with amyopathic and myopathic dermatomyositis. Arthritis Care Res. 2016;68:689–94.

15. Allenbach Y, Uzunyan H, Toquet S, Leroux G, Gallay L, Marquet A, et al. Different phenotypes in dermatomyositis associated with anti-MDA5 antibody: study of 121 cases. Neurology. 2020;95:e70–8.

16. Gono T, Kawaguchi Y, Ozeki E, Ota Y, Satoh T, Kuwana M, et al. Serum ferritin correlates with activity of anti-MDA5 antibody-associated acute interstitial lung disease as a complication of dermatomyositis. Mod Rheumatol. 2011;21:223–7.

17. Horai Y, Koga T, Fujikawa K, Takatanai A, Nishino A, Nakashima Y, et al. Serum interferon-α is a useful biomarker in patients with anti-melanoma differentiation-associated gene 5 (MDA5) antibody-positive dermatomyositis. Mod Rheumatol. 2015;25:85–9.

18. Shimizu T, Koga T, Furukawa K, Horai Y, Fujikawa K, Okada A, et al. IL-15 is a biomarker involved in the development of rapidly progressive interstitial lung disease complicated with polymyositis/dermatomyositis. J Intern Med. 2020. https://doi.org/10.1111/joim.13154

19. Eriksen JL, Mackenzie IR. Progranulin: normal function and role in neurodegeneration. J Neurochem. 2008;104:287–97.

20. He Z, Bateman A. Progranulin (granulin-epithelin precursor, PC-cell-derived growth factor, acrogranin) mediates tissue repair and tumorigenesis. J Mol Med. 2003;81:600–12.

21. Tanaka A, Tsukamoto H, Mitoma H, Kiyohara C, Ueda N, Ayano M, et al. Serum progranulin levels are elevated in patients with systemic lupus erythematosus, reflecting disease activity. Arthritis Res Ther. 2012;14:R244.

22. Chen J, Li S, Shi J, Zhang L, Li J, Chen S, et al. Serum progranulin is related with Breg cell levels, but elevated in RA patients, reflecting high disease activity. Rheumatol Int. 2016;36:359–64.

23. Tanaka A, Tsukamoto H, Mitoma H, Kiyohara C, Ueda N, Ayano M, et al. Serum progranulin levels are elevated in dermatomyositis patients with acute interstitial lung disease, predicting prognosis. Arthritis Res Ther. 2015;17:27.

24. Bohan A, Peter JB. Polymyositis and dermatomyositis (first of two parts). N Engl J Med. 1975;292:344–7.

25. Bohan A, Peter JB. Polymyositis and dermatomyositis (second of two parts). N Engl J Med. 1975;292:403–7.

26. Sontheimer RD. Would a new name hasten the acceptance of amyopathic dermatomyositis (dermatomyositis siné myositis) as a distinctive subset within the idiopathic inflammatory dermatomyopathies spectrum of clinical illness? J Am Acad Dermatol. 2002;46:626–36.

27. Lundberg IE, Tjärnlund A, Bottai M, Werth VP, Pilkington C, Visser M, et al. 2017 European League Against Rheumatism/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups. Ann Rheum Dis. 2017;76:1955–64.

28. Park B, Buti L, Lee S, Matsuwaki T, Spooner E, Brinkmann MM, et al. Granulin is a soluble cofactor for Toll-like receptor 9 signaling. Immunity. 2011;34:505–13.

29. Kessenbrock K, Dau T, Jenne DE. Tailor-made inflammation: how neutrophil serine proteases modulate the inflammatory response. J Mol Med. 2011;89:23–8.

30. Bilgic H, Ytterberg SR, Amin S, McNallan KT, Wilson JC, Koeuth T, et al. Interleukin-6 and type i interferon-regulated genes and chemokines mark disease activity in dermatomyositis. Arthritis Rheum. 2009;60:3436–46.

31. Nara M, Komatsuda A, Omokawa A, Togashi M, Okuyama S, Sawada K, et al. Serum interleukin 6 levels as a useful prognostic predictor of clinically amyopathic dermatomyositis with rapidly progressive interstitial lung disease. Mod Rheumatol. 2014;24:633–6.

32. He Z, Ong CH, Halper J, Bateman A. Progranulin is a mediator of the wound response. Nat Med. 2003;9:225–9.

33. Tang W, Lu Y, Tian QY, Zhang Y, Guo FJ, Liu GY, et al. The growth factor progranulin binds to TNF receptors and is therapeutic against inflammatory arthritis in mice. Science. 2011;332:478–84.

34. Yin F, Banerjee R, Thomas B, Zhou P, Qian L, Jia T, et al. Exaggerated inflammation, impaired host defense, and neuropathology in progranulin-deficient mice. J Exp Med. 2010;207:117–28.

35. Kessenbrock K, Fröhlich L, Sixt M, Lämmерmann T, Pfister H, Bateman A, et al. Proteinase 3 and neutrophil elastase enhance inflammation in mice by inactivating anti-inflammatory progranulin. J Clin Invest. 2008;118:2438–47.

36. Nakajima H, Harigai M, Hara M, Hakoda M, Tokuda H, Sakai F, et al. KL-6 as a novel serum marker for interstitial pneumonia associated with collagen diseases. J Rheumatol. 2000;27:1164–70.

How to cite this article: Fujii A, Mizutani YH, Kawamura M, et al. Serum progranulin level is a novel tool for monitoring disease activity of dermatomyositis with anitmelanoma differentiation-associated protein 5 antibodies. J Cutan Immunol Allerg. 2021;4:50–56. https://doi.org/10.1002/cia2.12160